Blackstone provides $1.3B financing to Apogee to advance potential Dupixent rival.
Blackstone is providing up to $1.3 billion in financing to Apogee to help the biotech company develop a potential competitor to the drug Dupixent.
Quick reaction
One tap helps tune what we surface next.
Reader discussion
Public commentsNo comments yet. Start the discussion around this signal.
Follow this signal
Get updates on this story
We will email you if this changes materially. No spam. Daily brief optional.
Map context
Open map near US
Keep the story in context with nearby live signals, countries, and category movement.
Related coverage
More story pages
Samsung pay deal signals seismic shift in South Korea's labor relations, boosting union power
A new pay deal at Samsung marks a significant shift in South Korea's labor landscape, strengthening union influence.
PDD Holdings Q1 revenue rose 11% YoY to $15.7B, missing $16.2B estimates; net profit fell 15% to $1.85B amid fierce competition in China.
Temu owner PDD Holdings reported Q1 revenue up 11% YoY to ~$15.7B, missing estimates of ~$16.2B. Net profit fell 15% to ~$1.85B, also below expectations, amid fierce competition in China.
ECB's Santos Pereira: Middle East conflict expected to significantly impact price developments.
ECB's Santos Pereira said the conflict in the Middle East is expected to have a significant impact on price developments.
Croatia nominates Ante Zigman to lead central bank, granting him a seat on the ECB's Governing Council.
Croatia has nominated Ante Zigman to lead its central bank, a role that includes a seat on the European Central Bank's Governing Council.
More live signals
Continue with the live feed.
The fastest nearby updates load from the public feed, not the enriched story endpoint.